ArticleHuman genomics2026
The global burden of ischemic heart disease attributable to trans fatty acid in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Barriers and Facilitators to the Use of Novel Injectable Lipid-Lowering Therapies in Patients with Dyslipidemia or Cardiovascular Disease: A Scoping Review.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIschemic heart disease (IHD) remains the leading global cause of mortality. This study aims to quantify the spatiotemporal trends, socioeconomic disparities, and future burden of trans fatty acid (TFA)-attributabfle IHD from 1990 to 2023.
methodsUsing Global Burden of Disease Study 2023 data, we extracted deaths, age-standardized mortality rates (ASMRs), disability-adjusted life-years (DALYs), and age-standardized DALY rates (ASDRs) for TFAs-attributable IHD across 204 countries/territories. DALYs combined years of life lost and years lived with disability to quantify total health loss. Outcomes were presented as counts and age-standardized rates per 100,000 population with 95% uncertainty intervals, stratified by age, sex, socio-demographic index (SDI), and region. Bayesian Age-Period-Cohort modeling projected ASMR and ASDR through 2050.
resultsTFAs contributed to 389.2 thousand (20.9–760.5 thousand) IHD deaths globally in 2023. Since 1990, global ASMR and ASDR declined by 45.7% (− 63.8 to − 1.4%) and 46.6% (− 64.2 to − 22.0%), respectively, masking profound geographical inequities. The burden was concentrated in Eastern Europe and South Asia, with stagnation in middle-SDI regions and the highest burden in low-middle-SDI regions. Males exhibited consistently higher burdens. Projections indicated decelerating declines approaching a plateau by 2050.
conclusionGlobal reductions in TFA-attributable IHD mask complex inequities, with disproportionate burdens in Eastern Europe and South Asia, and variable progress across SDI nations. Accelerating progress in these regions requires implementation of WHO REPLACE strategies, including mandatory limits on industrial TFAs and front-of-pack warning labels. Our population-level findings provide a foundation for future genomic studies of genetic susceptibility to TFA-induced cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.